Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

The pharmaceutical company has received tentative approval from the USFDA to manufacture Enzalutamide tablets in 40 mg and 80 ...

Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer ...

Opens in a new tab or window Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...